INmune Bio, Inc. - INMB
About Gravity Analytica
Recent News
- 05.07.2026 - INmune Bio Inc. Announces First Quarter 2026 Results and Provides Business Update
- 05.05.2026 - INmune Bio and Anthony Nolan Announce Strategic Expansion of CORDStrom™ MSC Platform Collaboration to Target RDEB, Oncology, and Inflammatory Diseases
- 03.30.2026 - INmune Bio Inc. Announces 2025 Results and Provides Business Update
- 03.19.2026 - INmune Bio’s MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation in Early Alzheimer’s Disease
- 02.23.2026 - INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer’s Webinar
- 02.19.2026 - INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom™ for RDEB
- 02.12.2026 - INmune Bio Announces FDA Alignment on Integrated Phase 2b/3 Registration Pathway for XPro1595 in Early Alzheimer’s Disease
- 02.10.2026 - INmune Bio Advances CORDStrom™ Towards UK Marketing Authorization in RDEB
Recent Filings
- 05.05.2026 - EX-99.1 EX-99.1
- 05.05.2026 - 8-K Current report
- 04.23.2026 - DEF 14A Other definitive proxy statements
- 03.30.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
- 02.27.2026 - 8-K Current report
- 02.27.2026 - EX-99.1 EX-99.1
- 02.23.2026 - 8-K Current report
- 02.23.2026 - EX-99.1 EX-99.1
- 02.19.2026 - 8-K Current report
- 02.19.2026 - EX-99.1 EX-99.1